SCHEMBL754847

SCHEMBL754847

Clc1ccc(I)cc1CBr

nearest known ligand 0.41

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 3/20 0.41
PNMT P11086 1/20 0.33
TAAR1 Q96RJ0 1/20 0.31
SLC6A2 P23975 1/20 0.31
SLC6A4 P31645 1/20 0.31
SLC6A3 Q01959 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640377 0.82 IDO1 (0.55) IDO1
SCHEMBL24732807 0.79 IDO1 (0.42) IDO1PNMTTAAR1
SCHEMBL29809253 0.79 IDO1 (0.42) IDO1PNMTTAAR1
SCHEMBL566305 0.78 IDO1 (0.36) IDO1SLC6A2SLC6A4
SCHEMBL3729703 0.77 PNMT (0.54) IDO1PNMTTAAR1
SCHEMBL30822631 0.77 IDO1 (0.41) IDO1PNMTTAAR1SLC6A2SLC6A4
SCHEMBL1767780 0.77 IDO1 (0.41) IDO1PNMTTAAR1SLC6A2SLC6A4
SCHEMBL8225128 0.77 IDO1 (0.41) IDO1PNMTSLC6A4
SCHEMBL13077676 0.77 IDO1 (0.41) IDO1PNMTTAAR1SLC6A4
SCHEMBL189771 0.76 TP53 (0.48) IDO1SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109232199-B Synthesis method of 1-chloro-2- (4-ethoxybenzyl) -4-iodobenzene 南京红杉生物科技有限公司 2021-11-30 CN claimed
CN-109232199-A The chloro- 2-(4- ethoxy benzyl of 1-) -4- iodobenzene synthetic method 南京红杉生物科技有限公司 2019-01-18 CN claimed
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-12-25 US disclosed
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2025-02-27 US disclosed
US-20250042930-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG SICHUAN UNIVERSITY (CN) 2025-02-06 US disclosed
US-12084472-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists ARDELYX, INC. (US) 2024-09-10 US disclosed
WO-2023213035-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG 四川大学 2023-11-09 WO disclosed
CN-116730998-A Process for preparing aryl carbon glycoside compound 四川大学华西医院 2023-09-12 CN disclosed
US-20220306672-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX, INC. (US) 2022-09-29 US disclosed
EP-3390382-B1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS ARDELYX INC (US) 2021-12-01 EP disclosed
CN-109232199-B Synthesis method of 1-chloro-2- (4-ethoxybenzyl) -4-iodobenzene 南京红杉生物科技有限公司 2021-11-30 CN disclosed
US-20100120714-A1 SUBSTITUTED BENZENE FUNGICIDES E.I. DU PONT DE NEMOURS AND COMPANY (US) 2010-05-13 US disclosed
CN-101686688-A substituted benzene fungicides DU PONT 2010-03-31 CN disclosed
EP-2129225-A2 SUBSTITUTED BENZENE FUNGICIDES E. I. Du Pont de Nemours and Company (US) 2009-12-09 EP disclosed
WO-2008124092-A2 SUBSTITUTED BENZENE FUNGICIDES E. I. DU PONT DE NEMOURS AND COMPANY (US) 2008-10-16 WO disclosed
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. 2008-08-21 US disclosed
WO-2008100618-A2 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S SUNESIS PHARMACEUTICALS, INC. (US) 2008-08-21 WO disclosed
US-20070232626-A1 Purine Derivatives as A3 and A1 Adenosine Receptor Agonists GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND H (MD) 2007-10-04 US disclosed
EP-1794162-A1 PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS The Government of the United States of America, as repres. by the Secretary of Health and Human Services, Nat. Inst. of Health (US) 2007-06-13 EP disclosed
WO-2006031505-A1 PURINE DERIVATIVES AS A3 AND A1 ADENOSINE RECEPTOR AGONISTS GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066410-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R IDO1 1111/4885PNMT 1139/4885TAAR1 169/4885
US-20250388615-A9 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, FFAR3 IDO1 1416/4885PNMT 2080/4885TAAR1 86/4885
US-20250042930-A1 METHOD FOR PREPARING ARYL CARBON GLYCOSIDE COMPOUND INCLUDING GLIFLOZIN DRUG UGGT1, GCG, SLC5A2 IDO1 1708/4885PNMT 4628/4885TAAR1 4719/4885
US-20080200454-A1 CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S CTSS, CTSK, CTSZ IDO1 2941/4885PNMT 3898/4885TAAR1 3251/4885
US-20220306672-A1 SUBSTITUTED 4-PHENYL PYRIDINE COMPOUNDS AS NON-SYSTEMIC TGR5 AGONISTS GPR119, GIPR, GLP1R IDO1 1111/4885PNMT 1139/4885TAAR1 169/4885
US-12084472-B2 Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists GPR119, GIPR, GLP1R IDO1 1111/4885PNMT 1139/4885TAAR1 169/4885
US-20070232626-A1 Purine Derivatives as A3 and A1 Adenosine Receptor Agonists ADORA1, ADORA3, ADORA2A IDO1 3225/4885PNMT 2219/4885TAAR1 130/4885
US-20100120714-A1 SUBSTITUTED BENZENE FUNGICIDES NR0B1, CBR3, NR0B2 IDO1 1241/4885PNMT 3469/4885TAAR1 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.